HCLTECH
16.1.2023 13:14:41 CET | Business Wire | Press release
HCLTech, a leading global technology company, is joining governments, businesses and civil society from across the world at the World Economic Forum (WEF) 2023 in Davos to facilitate dialogue and collaboration for a sustainable planet and inclusive growth.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230116005173/en/
HCLTech pavilion at Promenade66, Davos (Photo: Business Wire)
HCLTech is proud of its long-standing strategic partnership with the WEF. The HCLTech Pavilion at WEF 2023 showcases the company’s new brand identity and purpose of bringing together the best of technology and people to supercharge progress for clients, its people, communities and the planet.
Located at Promenade 66, 7270 Davos Platz, the HCLTech Pavilion is fully powered by green energy, underscoring the company’s commitment to a sustainable planet.
As part of HCLTech’s focus on diversity and gender equality, the company is hosting the UN Women’s Gender Equality Hub at its Pavilion. The Hub will feature daily video check-ins, pop-up panel discussions and fireside chats.
HCLTech’s leadership team will join and host global leaders at WEF in thought-provoking sessions around the Annual Meeting’s theme of “Cooperation in a Fragmented World” and discuss solutions to address the diverse crises facing the world.
Roshni Nadar Malhotra, Chairperson, HCLTech will join former U.S. Vice President Al Gore and other distinguished leaders at “Leading the Charge through Earth’s New Normal” - a session to discuss transformative solutions and global collaboration to build a more inclusive, prosperous and sustainable future. She will also join “The Aquapreneur Revolution” - a session hosted by Emma Benameur, Head of Impact and Engagement and Member of the WEF Executive Committee to announce the winners of The Global Freshwater Innovation Challenge under HCL Group and UpLink’s quest to find innovative solutions for freshwater conservation.
C Vijayakumar, CEO & Managing Director, HCLTech will share his vision at “Preparing One Billion People for Tomorrow’s Economy” - a session to discuss critical interventions needed to skill one billion people by 2030 in a world being rapidly transformed by technology. He will be joined by Saadia Zahidi, Managing Director, WEF and business leaders from Merck, Manpower Group and UBA Group.
In addition, Santhosh Jayaram, Global Head of Sustainability, HCLTech will spearhead the “Sustainability Dialogues with HCLTech” - a series of sessions with industry-leading business and thought leaders to engage in an open dialogue, focused on the most pressing agendas and topics around sustainability.
Srinivasan Seshadri, Corporate Vice President and Global Head of Financial Services, HCLTech will be part of “Operating Models in the Wake of Deglobalization” - a session on the growing need of businesses for innovative models to insulate them from the growing volatility in the global environment.
HCLTech CMO Jill Kouri will speak at “Generation Equality Pop Up, Role of Women in Climate Action” - a session that will include Kate Behncken, Corporate Vice President, Microsoft Philanthropies and Caitlin Kraft Buchman, Founder, CEO, Women@TheTable.
To learn more about HCLTech@WEF 2023 visit https://www.hcltech.com/world-economic-forum.
About HCLTech
HCLTech is a global technology company, home to 222,000+ people across 60 countries, delivering industry-leading capabilities centered around digital, engineering and cloud, powered by a broad portfolio of technology services and products. We work with clients across all major verticals, providing industry solutions for Financial Services, Manufacturing, Life Sciences and Healthcare, Technology and Services, Telecom and Media, Retail and CPG and Public Services. Consolidated revenues as of 12 months ending December, 2022 totaled $12.3 billion. To learn how we can supercharge progress for you, visit hcltech.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230116005173/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom